Skip to main content

Advertisement

Log in

Network pharmacology of apigeniflavan: a novel bioactive compound of Trema orientalis Linn. in the treatment of pancreatic cancer through bioinformatics approaches

  • Original Article
  • Published:
3 Biotech Aims and scope Submit manuscript

Abstract

Pancreatic cancer is the seventh most prevalent cause of mortality globally. Since time immemorial, plant-derived products have been in use as therapeutic agents due to the existence of biologically active molecules called secondary metabolites. Flavonoids obtained from plants participate in cell cycle arrest, induce autophagy and apoptosis, and decrease oxidative stress in pancreatic cancer. The present study involves network pharmacology-based study of the methanolic leaf extract of Trema orientalis (MLETO) Linn. From the high-resolution mass spectrometry (HRMS) analysis, 21 nucleated flavonoids were screened out, of which only apigeniflavan was selected for further studies because it followed Lipinski’s rule and showed no toxicity. The pharmacokinetics and physiochemical characteristics of apigeniflavan were performed using the online web servers pkCSM, Swiss ADME, and ProTox-II. This is the first in silico study to report the efficiency of apigeniflavan in pancreatic cancer treatment. The targets of apigeniflavan were fetched from SwissTargetPrediction database. The targets of pancreatic cancer were retrieved from DisGeNET and GeneCards. The protein–protein interaction of the common genes using Cytoscape yielded the top five hub genes: KDR, VEGFA, AKT1, SRC, and ESR1. Upon molecular docking, the lowest binding energies corresponded to best docking score which indicated the highest protein–ligand affinity. Kyoto Encyclopaedia of Genes and Genomes (KEGG) database was employed to see the involvement of hub genes in pathways related to pancreatic cancer. The following, pancreatic cancer pathway, MAPK, VEGF, PI3K–Akt, and ErbB signaling pathways, were found to be significant. Our results indicate the involvement of the hub genes in tumor growth, invasion and proliferation in the above-mentioned pathways, and therefore necessitating their downregulation. Moreover, apigeniflavan can flourish as a promising drug for the treatment of pancreatic cancer in future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig.1
Fig.2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

Data availability

Public databases have the data needed to validate the findings of this study.

Abbreviations

HRMS:

High-resolution mass spectrometry

MLETO:

Methanolic leaf extract of Trema orientalis

KEGG:

Kyoto encyclopaedia of genes and genomes

ROS:

Reactive oxygen species

PPI:

Protein–protein interaction

ADME:

Absorption, distribution, metabolism, and excretion

HBD:

Hydrogen bond donor

HBA:

Hydrogen bond acceptor

TPSA:

Topological polar surface area

DL:

Druglikeness

MR:

Molar refractivity

HIA:

Human intestinal absorption

BBB:

Blood–brain barrier

CNS:

Central nervous system

OCT2:

Organic cation transporter 2 substrate

CYP2D6:

CYP2D6 Cytochrome P450 2D6

CYP3A4:

Cytochrome P450 3A4

hERG:

Human ether-a-go-go related gene

LOAEL:

Lowest-observed adverse-effect level

LD50:

Lethal dose 50

TCMSP:

Traditional Chinese medicine systems pharmacology database and analysis platform

STRING:

Search tool for the retrieval of interacting genes/proteins

GO:

Gene ontology

DAVID:

Database for annotation, visualization and integrated discovery

GEPIA:

Gene expression profiling interactive analysis

MW:

Molecular weight

ADMET:

Absorption, distribution, metabolism, excretion, and toxicity

References

Download references

Acknowledgements

The author, Richa Das, gratefully acknowledges the Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology, Banaras Hindu University, and Parul Institute of Applied Science, Parul University, for their immense support.

Funding

No specific grant was received for this work by funding organizations in the public, private, or not-for-profit sectors.

Author information

Authors and Affiliations

Authors

Contributions

SKM and KNT: developed the concept and design of the work. RD, SA, PK, and AKS: data collection, analysis, and interpretation of results. IB, AKT, and KNT: revision of manuscript. PKS: fractionation.

Corresponding author

Correspondence to Sunil Kumar Mishra.

Ethics declarations

Conflict of interest

The author declares no conflict of interest.

Ethical approval

This study did not involve the use of any human or animal model.

Informed consent

Not applicable.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Das, R., Agrawal, S., Kumar, P. et al. Network pharmacology of apigeniflavan: a novel bioactive compound of Trema orientalis Linn. in the treatment of pancreatic cancer through bioinformatics approaches. 3 Biotech 13, 160 (2023). https://doi.org/10.1007/s13205-023-03570-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13205-023-03570-7

Keywords

Navigation